Josh Riff Leaves Onduo; Thoughts on AgaMatrix+Bayer for China, and Confusion on Cascade CGM Wear Time in Europe

Two diabetes-related news items have been observed: Onduo announced the departure of CEO Josh Riff and AgaMatrix Holdings announced a corporate name change to “WaveForm Diabetes,” the appointment of a new Executive Chairman and CEO, Rick Valencia, and a partnership in China with Bayer for its CGM distribution. Below, FENIX provides thoughts on the leadership appointments in Onduo and WaveForm, as well as insight into the somewhat ironic partnership between WaveForm and Bayer, and some observed confusion on 15-day vs. 14-day wear time from Menarini’s product materials.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.